

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



HANGZHOU TIGERMED CONSULTING CO., LTD.

杭州泰格醫藥科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 3347)

**ELECTION OF EMPLOYEE DIRECTOR TO
THE FIFTH SESSION OF THE BOARD**

Reference is made to the announcement of Hangzhou Tigermед Consulting Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) dated August 28, 2025 in relation to, inter alia, proposed amendments to the Articles of Association of the Company (the “**Articles of Association**”). Pursuant to the proposed amendments to the Articles of Association, inter alia, the board (the “**Board**”) of directors (the “**Director(s)**”) of the Company shall comprise seven Directors, including one employee Director (the “**Proposed Amendments**”).

The Board hereby announces that, in light of the adjustment in governance structure as introduced in the Proposed Amendments, and with a view to ensure compliant operation of the Board, on August 28, 2025, upon election by the employee representative meeting of the Company, Mr. Wu Hao (吳灝) (“**Mr. Wu**”), an executive Director, was elected as the employee Director of the fifth session of the Board, with his term of office commencing from the date of approval of the Proposed Amendments by the general meeting of the Company and up to the expiry of the term of the fifth session of the Board. Mr. Wu Hao will also continue to serve as an executive Director and a member of the strategy development committee of the Board.

The biographical details of Mr. Wu Hao is set out as follows:

Mr. Wu Hao, aged 58, joined the Group in January 2020 and is currently an executive Director, co-president and a member of the strategy development committee of our Company. Mr. Wu was appointed as our executive Director in October 2021.

Mr. Wu has over 17 years of experience in the pharmaceutical industry and has extensive marketing and managerial experience. Prior to joining the Group, Mr. Wu served successively as sales manager and a product/project manager of Schering Plough Pharmaceutical Co., Ltd.* (先靈葆雅製藥有限公司) from August 1994 to October 1999, product manager of Shanghai Roche Pharmaceutical Co., Ltd.* (上海羅氏製藥有限公司) from October 1999 to December 2002, marketing director of Eisai China Inc.* (衛材(中國)製藥有限公司) from January 2003 to July 2007, director of marketing and business development department of SciClone International Pharmaceutical Co., Ltd.* (賽生國際製藥有限公司) from August 2007 to January 2009 and the general manager of Meixin Insurance Broker (Shanghai) Co., Ltd.* (美信保險經紀(上海)有限公司) from March 2010 to January 2020. Mr. Wu has been a non-executive director of Frontage Holdings Corporation (a company listed on the Stock Exchange with stock code: 1521) since June 1, 2022.

Mr. Wu obtained his bachelor's degree in clinical medicine from Shanghai Jiao Tong University School of Medicine (formerly known as Shanghai Second Medical University) in 1992 and an EMBA degree from China Europe International Business School in 2009.

The Company has been entered into an employment contract with Mr. Wu. The remuneration of Mr. Wu in relation to his role in the Company is determined by the Board according to the remuneration policy of the Company and with reference to his duties and responsibilities within the Group as well as his qualifications and experience. His emoluments was approximately RMB1.96 million for the year ended December 31, 2024. Mr. Wu will not receive remuneration for his role as an employee Director. The remuneration of Mr. Wu will be disclosed in the annual report of the Company for the relevant year.

Mr. Wu has confirmed that, save as disclosed above, he (i) does not hold any other position in the Company and any of its subsidiaries; (ii) has not held any directorship in the last three years in public companies, the securities of which are listed on any securities market in Hong Kong or overseas; (iii) has no other major appointment and professional qualification; (iv) does not have any other relationship with any Director, senior management or substantial or controlling shareholder of the Company; and (v) does not have, or is not deemed to have, any interests in any shares or underlying shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed in this announcement, the Board is not aware of any other matter in relation to the appointment of Mr. Wu which is required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and any other matter that needs to be brought to the attention of the shareholders of the Company.

By order of the Board
Hangzhou Tigermed Consulting Co., Ltd.
Ye Xiaoping
Chairman

Hong Kong, August 28, 2025

As at the date of this announcement, the executive Directors are Dr. Ye Xiaoping, Ms. Cao Xiaochun, Mr. Wu Hao and Mr. Wen Zengyu; the independent non-executive Directors are Mr. Liu Kai Yu Kenneth, Mr. Yuan Huagang and Ms. Liu Yuwen.